Skip to content
Study details
Enrolling now

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Hope Biosciences LLC
NCT IDNCT05951777ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

51

Study length

about 2.7 years

Ages

18–55

Locations

2 sites in TX

What this study is about

Researchers are testing a treatment with autologous HB-adMSCs to see if it can improve brain structure, cognitive function, and reduce inflammation after traumatic brain injury. The trial will last about 989 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Autologous HB-adMSCs
  • 2.Take Normal Saline

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Alanine aminotransferase, Aspartate aminotransferase, Creatinine, Glucose

Secondary: Brief Symptom Inventory 18, Interleukin 6, PET/DT-MRI (positron emission tomography/Diffusion tensor-Magnetic resonance imaging), TBI (Traumatic Brain Injury) Quality of Life Questionnaires, Whole brain MRI (Magnetic resonance imaging)